Nigeria receives $133m grant to fight HIV/AIDS, tuberculosis
Nigeria has received a grant of $133 million from the Global Fund to fight HIV/AIDS, tuberculosis, and malaria from January 2024 to 2026.
The Acting Executive Secretary, Country Coordinating Mechanism for Global Fund Nigeria, Ibrahim Tajudeen made this known in Abuja on Monday during a press briefing on the impact of the global fund and other partners on NAFDAC’s regulatory system strengthening.
The Global Fund is an international financing institution dedicated to combating HIV/AIDS, Tuberculosis, and Malaria.
Mr Tajundeen said Nigeria was able to secure the grant because of the judicious use of previous grants.
Giving the breakdown of the grant received from the Global fund for the period of 2021 to 2023, the Director General of National Agency for Food and Drug Administration and Control (NAFDAC), Prof Mojisola Adeyeye explained that out of the $2.3 million received, over $1 million was used for tracking and tracing of vaccine and non-vaccine products as well as building capacity of stakeholders.
‘’Another impactful support from GF was the support to NAFDAC for phased implementation of traceability of health products ($1,131,328.82 BL136): This budget line has been instrumental in rolling out a phased implementation of traceability for health products in Nigeria. This budget line supported: a total of 1,561 stakeholders were trained across 36 states and the FCT comprising 832 in the public sector and 729 in the private sector.
”Deployment of 435 android-enabled mobile android scanners and 315 internet routers to support traceability of ATM commodities’’, she explained.
Prof Adeyeye further said three NAFDAC state offices were supported with three field devices for on-the-spot checks for product quality with about $ 1 million used to strengthen the Central Drug Control Laboratory in Yaba.
”Strengthening NAFDAC role and capacity in pharmacovigilance and ADR monitoring and reporting ($36,965.00): Over the years, NAFDAC has invested in the capacity building of staff in pharmacovigilance (PV). However, in ensuring sustained delivery of its mandate, the skills and competence of its staff require continuous capacity strengthening and advancement. NAFDAC has successfully built the capacity of 76 staff members across 36+1 states on the pharmacovigilance of AIDS, Tuberculosis, and Malaria (ATM) commodities.
”In addition, GF (BL 106) supported NAFDAC in acquiring a mobile app for ADR reporting and monitoring pharmacovigilance activity for three years ending in 2023 ($8,684.21): The implementation of a mobile app has streamlined the reporting and monitoring of adverse drug reactions (ADR) and improved the overall responsiveness of the healthcare system.”
The NAFDAC DG commended donor partners and pledged commitment to safe and quality health products for Nigerians.
The Director General of National Agency for the Control of AIDS (NACA), Dr Gambo Aliyu who explained that the $ 2.3 million was domiciled with the Agency, expressed satisfaction with its utilisation, saying it was a true definition of value for money.
Mr Aliyu also said that NACA does not only provide support for HIV/AIDS but for all national responses, as was evident during the COVID-19 pandemic and the Ebola outbreak.
Comments
Post a Comment